James N. Kochenderfer, M.D.

James N. Kochenderfer, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Surgery Branch


Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies. Chimeric antigen receptors (CARs) are fusion proteins that recognize malignant cells. T cells genetically engineered to express CARs can be infused into patients to treat cancer. Dr. Kochenderfer leads laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and for treatment of B-cell malignancies after allogeneic hematopoietic stem cell transplantation.

Areas of Expertise

1) chimeric antigen receptors 2) treatment of lymphoma, leukemia, and multiple myeloma 3) T-cell immunology 4) gene therapy 5) immunotherapy 6) hematopoietic stem cell transplantation

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Recent Publications

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN
N Engl J Med. 380: 1726-1737, 2019. [ Journal Article ]

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Brudno JN, Kochenderfer JN
Blood. 34: 45-55, 2019. [ Journal Article ]

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA
J Clin Oncol. 35: 1803-1813, 2017. [ Journal Article ]

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN
J Clin Oncol. 34: 1112-21, 2016. [ Journal Article ]

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN.
J Clin Oncol. 36/22: 2267-2280, 2018. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.


Postdoctoral Fellow (Visiting)
Christina Amatya, Ph.D.
Medical Oncology Clinical Fellow
Kathryn Cappell, M.D.
Research Nurse
Ashley Carpenter, R.N.
Postbaccalaureate Fellow (CRTA)
Stephanie Choi, B.S.
Research Nurse
Micaela Ganaden, R.N.
Research Nurse
Brenna Hansen, R.N.
Research Nurse (Contr.)
Jo Hurtt, R.N.
Norris Lam, B.S.
Nurse Practitioner
Jennifer Mann, CRNP
Patient Care Coordinator (Contr.)
Rachael Mohn, B.S.
Research Technician (Contr.)
Danielle Vanasse, B.S.
Principal Scientist (Contr.)
Shicheng Yang, Ph.D.